Technical Lead Architect - CTI MD Tech (GRA/GSC)
Eli Lilly and Company11 hours ago
Bengaluru, IndiaStaff+
Responsibilities
- Lead transformation of regulatory and scientific communications processes into AI-driven, agentic workflows with human-in-the-loop checkpoints.
- Own AI, generative AI, and agentic AI strategy across the GRA/GSC portfolio.
- Establish governance, operating models, and architectural patterns for secure, cyber-hardened AI and agentic workflows.
- Own the portfolio technology strategy, roadmap, investment plan, and future-state technology vision.
- Partner with business and portfolio leadership on capability planning, prioritization, and technology opportunities.
- Evaluate emerging technologies and lead portfolio rationalization, modernization, and simplification.
- Create reusable architecture patterns and reference models that improve delivery speed and sustainability.
- Ensure solutions are scalable, secure, resilient, compliant, and aligned with enterprise architecture standards.
- Mentor technical leaders, architects, and engineering teams.
Requirements
- Proven track record developing and executing enterprise technology strategies.
- Demonstrated success leading large-scale digital transformation initiatives involving AI-driven and agentic automation.
- Experience driving technology investments, portfolio modernization, and architecture governance.
- Experience leading through ambiguity, complexity, and organizational transformation.
- Experience in both Global Regulatory Affairs and Scientific Communications.
- Familiarity with Regulatory Content and Submission Management, Veeva RIM, and regulatory platforms.
- Experience with document and content management ecosystems.
- Background in pharma and GxP-regulated environments.
Tech Stack
Categories
About Eli Lilly and Company
Eli Lilly and Company researches, develops, manufactures, and markets prescription medicines and biologics for patients, sold through healthcare providers, pharmacies, and payers. Core therapeutic areas include diabetes, oncology, immunology, neuroscience, and obesity. Founded in 1876 and headquartered in Indianapolis, it is a public company (NYSE: LLY) with global operations and is building a new advanced manufacturing site for gene therapy and other modalities in Lebanon, Indiana.